See more : Anheuser-Busch InBev SA/NV (1NBA.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Guardant Health, Inc. (GH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guardant Health, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- iTech Minerals Ltd (ITM.AX) Income Statement Analysis – Financial Results
- China Merchants Bank Co., Ltd. (CIHHF) Income Statement Analysis – Financial Results
- Alteryx, Inc. (0HDD.L) Income Statement Analysis – Financial Results
- Brookfield Infrastructure Partners L.P. (BIP-PE.TO) Income Statement Analysis – Financial Results
- Bloomage BioTechnology Corporation Limited (688363.SS) Income Statement Analysis – Financial Results
Guardant Health, Inc. (GH)
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 563.95M | 449.54M | 373.65M | 286.73M | 214.38M | 90.64M | 49.84M | 25.25M |
| Cost of Revenue | 227.05M | 156.33M | 122.91M | 92.54M | 70.72M | 43.21M | 31.62M | 22.12M |
| Gross Profit | 336.90M | 293.21M | 250.74M | 194.20M | 143.66M | 47.43M | 18.22M | 3.13M |
| Gross Profit Ratio | 59.74% | 65.23% | 67.11% | 67.73% | 67.01% | 52.33% | 36.56% | 12.38% |
| Research & Development | 367.19M | 373.81M | 263.22M | 149.86M | 86.29M | 50.71M | 25.56M | 10.86M |
| General & Administrative | 155.80M | 163.96M | 206.64M | 192.77M | 61.40M | 36.19M | 36.78M | 9.92M |
| Selling & Marketing | 295.23M | 299.83M | 191.88M | 106.51M | 78.34M | 53.47M | 32.50M | 26.19M |
| SG&A | 451.03M | 463.78M | 398.52M | 299.28M | 139.73M | 89.66M | 69.27M | 36.11M |
| Other Expenses | 83.40M | -112.56M | 25.18M | 3.64M | 88.00K | 4.70M | -1.06M | -1.00K |
| Operating Expenses | 901.62M | 837.59M | 661.74M | 449.15M | 226.03M | 140.37M | 94.84M | 46.97M |
| Cost & Expenses | 1.13B | 993.92M | 784.65M | 541.68M | 296.75M | 183.58M | 126.45M | 69.10M |
| Interest Income | 35.37M | 6.07M | 3.93M | 10.17M | 13.74M | 5.27M | 2.23M | 733.00K |
| Interest Expense | 2.58M | 2.58M | 2.58M | 4.77M | 1.18M | 1.25M | 2.70M | 3.02M |
| Depreciation & Amortization | 42.88M | 35.96M | 22.27M | 16.07M | 13.61M | 7.14M | 5.21M | 3.69M |
| EBITDA | -433.31M | -614.91M | -359.62M | -225.07M | -54.93M | -75.84M | -75.31M | -39.42M |
| EBITDA Ratio | -76.83% | -144.79% | -102.21% | -84.10% | -31.97% | -91.54% | -140.91% | -156.13% |
| Operating Income | -564.73M | -544.38M | -411.00M | -254.95M | -82.37M | -92.94M | -76.61M | -43.85M |
| Operating Income Ratio | -100.14% | -121.10% | -110.00% | -88.92% | -38.42% | -102.54% | -153.71% | -173.66% |
| Total Other Income/Expenses | 85.96M | -109.07M | 26.53M | 9.05M | 12.65M | 8.72M | -6.60M | -2.29M |
| Income Before Tax | -478.76M | -653.45M | -384.47M | -245.90M | -69.72M | -84.23M | -83.21M | -46.13M |
| Income Before Tax Ratio | -84.90% | -145.36% | -102.89% | -85.76% | -32.52% | -92.92% | -166.96% | -182.71% |
| Income Tax Expense | 685.00K | 1.14M | 300.00K | 379.00K | -1.87M | 38.00K | 7.00K | 6.00K |
| Net Income | -479.45M | -654.59M | -384.77M | -246.28M | -67.85M | -85.06M | -83.22M | -46.14M |
| Net Income Ratio | -85.02% | -145.61% | -102.98% | -85.89% | -31.65% | -93.85% | -166.97% | -182.74% |
| EPS | -4.28 | -6.41 | -3.80 | -2.53 | -0.75 | -2.80 | -1.18 | -0.65 |
| EPS Diluted | -4.28 | -6.41 | -3.80 | -2.53 | -0.75 | -2.80 | -1.18 | -0.65 |
| Weighted Avg Shares Out | 111.99M | 102.18M | 101.31M | 97.50M | 90.60M | 30.40M | 70.72M | 70.72M |
| Weighted Avg Shares Out (Dil) | 111.99M | 102.18M | 101.31M | 97.50M | 90.60M | 30.40M | 70.72M | 70.72M |
Guardant Health to Appeal Federal District Court Verdict
Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea
Guardant Health, Inc. (GH) Q3 2023 Earnings Call Transcript
Guardant Health (GH) Reports Q3 Earnings: What Key Metrics Have to Say
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
Guardant Health to Participate in Upcoming November Investor Conferences
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
Source: https://incomestatements.info
Category: Stock Reports